ARCH Venture Partners is a global venture capital firm specializing in investments within the life sciences, physical sciences, and advanced technology sectors. The firm typically engages in Series A, B, and C funding rounds, supporting companies with transformative potential. ARCH Venture Partners focuses on catalyzing scientific discoveries that prevent, detect, and cure diseases, investing substantial capital to foster innovation and growth.

Notable portfolio companies include Alnylam Pharmaceuticals, Illumina Inc., and Grail. Key partners and decision-makers at ARCH have a strong track record of building successful ventures, with affiliations to renowned companies such as Illumina and Juno Therapeutics. ARCH's investment philosophy emphasizes deep involvement and commitment to their portfolio companies, offering unique value-add services that include strategic guidance, operational support, and access to an extensive network of industry experts and resources.